- Chime Biologics and Waterstone announce strategic partnership to provide integrated ADC services.
- The collaboration focuses on offering comprehensive solutions for IND-enabling and clinical ADC studies.
Chime Biologics, a CDMO specialising in biologics, has entered a strategic partnership with Waterstone Pharmaceuticals to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. The partnership aims to support ADC developers in conducting IND-enabling and clinical studies, utilising each company’s specific expertise.
Through the collaboration, Chime Biologics will manage process development and cGMP manufacturing of Antibody Intermediate, ADC Drug Substance, and Drug Product. Waterstone will contribute by supplying Linker-payload, a critical component in ADC production. This combined service offering is designed to enhance ADC project efficiency and support ADC developers worldwide.
Dr. Faming Zhang, CEO of Waterstone, expressed optimism about the partnership, stating, “Our partnership with Chime Biologics is a significant milestone for Waterstone. Their expertise in antibody drug development and GMP manufacturing will be instrumental as we expand into global markets and advance our assets.”
Dr. Jimmy Wei, President of Chime Biologics, highlighted the growth potential this partnership represents, adding, “Currently, Chime Biologics has begun to undertake multiple ADC projects. This partnership will significantly advance our innovation and growth in the ADC field.”
Read about ADC Antibody Drug Conjugates CDMO Market 2024 Here.
Overview of outsourcing trends 
